Annual Drug Patent Expirations for JANUMET+XR
Janumet Xr is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for JANUMET XR.
This drug has one hundred and seventeen patent family members in forty-six countries.
The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. One supplier is listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
